SEARCH RESULTS FOR:

Servicing Your Every Need

United States Biopharmaceuticals 2019 Pre-Release Edition
Opportunities grow for contract service providers.

Debbie Hart

PRESIDENT AND CEO, BIONJ
United States Biopharmaceuticals 2019 Pre-Release Edition
Founded in 1994, BioNJ’s mission is to enhance the climate for the life sciences industry in the state.

Arda Ural

PHD PARTNER & OPERATIONAL TRANSACTION SERVICES LIFE SCIENCES LEADER - TRANSACTION ADVISORY SERVICES, ERNST AND YOUNG (EY)
United States Biopharmaceuticals 2019 Pre-Release Edition
EY is a multinational professional services firm headquartered in London, United Kingdom.

Annette Grimaldi

MANAGING DIRECTOR, LIFE SCIENCES INVESTMENT BANKING, BMO CAPITAL MARKETS
United States Biopharmaceuticals 2019 Pre-Release Edition

Philippe Cloutier

CEO, CARTIER RESOURCES
Québec Mining 2019 Pre-Release Edition
Cartier Resources is a junior gold exploration company focused on the Abitibi greenstone belt in Quebec.

Dean Journeaux

COFOUNDER AND BOARD MEMBER, NEW MILLENNIUM IRON (NML)
Québec Mining 2019 Pre-Release Edition
New Millennium Iron Corp. (NML) has actively explored properties in Canada's Labrador Trough and is now at the development stage.

Suresh Vadnagra

EXECUTIVE GM OPERATIONS AMERICAS, MMG; PRESIDENT, MINERA LAS BAMBAS
A look at the plan for Las Bambas, a 1st tier, world-class asset and MMG’s flagship operation.

Eugenio Manzano

EXECUTIVE DIRECTOR, POCHTECA
Latin America Petrochemicals and Chemicals 2018 APLA Special Edition
Pochteca offers a portfolio of over 7,300 industrial products to clients throughout Latin America.

Andrew Wilkins

VICE PRESIDENT, BUSINESS DEVELOPMENT AND MARKETING, DISTRIBUTED GAS SOLUTIONS CANADA (DGSC)
Québec Mining 2019
DGSC works with mining companies to provide customized supply solutions for dis-tributed Liquefied Natural Gas (LNG) and Compressed Natural Gas (CNG) across Canada.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS